EXHIBIT 5.1
![LOGO](https://capedge.com/proxy/8-K/0001193125-20-243154/g13911dsp50.jpg)
Writer’s Direct Dial: +1 212 225 2494
E-Mail: sflow@cgsh.com
September 10, 2020
American Tower Corporation
116 Huntington Avenue
Boston, Massachusetts 02116
Ladies and Gentlemen:
We have acted as special counsel to American Tower Corporation, a Delaware corporation (the “Company”), in connection with its offering pursuant to a registration statement on Form S-3 (No. 333-231931), as amended as of its most recent effective date (September 2, 2020), insofar as it relates to the Securities (as defined below) (as determined for purposes of Rule 430B(f)(2) under the Securities Act of 1933, as amended (the “Securities Act”)) (as so amended, including the documents incorporated by reference therein but excluding Exhibit 25, the “Registration Statement”) and the prospectus, dated June 4, 2019, as supplemented by the prospectus supplement thereto, dated September 2, 2020 (together, the “Prospectus”), of €750,000,000 aggregate principal amount of its 0.500% Senior Notes due 2028 (the “2028 Notes”) and €650,000,000 aggregate principal amount of its 1.000% Senior Notes due 2032 (the “2032 Notes” and, together with the 2028 Notes, the “Securities”). The Securities were issued under an indenture dated as of June 4, 2019 (the “Base Indenture”) between the Company and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented with respect to the Securities by Supplemental Indenture No. 5 thereto dated as of September 10, 2020 (the “Supplemental Indenture,” and together with the Base Indenture, the “Indenture”) between the Company, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent.
In arriving at the opinion expressed below, we have reviewed the following documents:
| (a) | the Registration Statement; |
![LOGO](https://capedge.com/proxy/8-K/0001193125-20-243154/g13911dsp50_2.jpg)